|FDA-APPROVED OVARIAN CANCER TREATMENTS|
|altretamine||Hexalen||50mg||caps||260mg/m² daily in four divided doses for either 14 or 21 consecutive days in a 28-day cycle|
|soln for IV infusion||Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles
Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
|cisplatin||—||1mg/mL||soln for IV infusion after dilution||75–100mg/m² IV per cycle once every 3–4wks on Day 1|
|50mg/vial||pwd for IV infusion after reconstitution and dilution|
|500mg, 1g, 2g||pwd for inj after reconsti–
|40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly|
|melphalan||Alkeran||2mg||scored tabs||0.2mg/kg/day for 5 days; repeat every 4–5wks|
|thiotepa||—||15mg||pwd for IV, intravesical, or intracavitary admini–
stration after reconsti–
|0.3–0.4mg/kg IV once every 1–4wks|
|doxorubicin||—||10mg, 20mg, 50mg||pwd for IV inj after reconsti–
|Monotherapy: 60–75mg/m² every 21 days
Combination therapy: 40–60mg/m² every 21 to 28 days
|2mg/mL||soln for IV inj|
|doxorubicin (liposomal)||Doxil||2mg/mL||dispersion for IV infusion after dilution||50mg/m² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.|
|gemcitabine||Gemzar||200mg, 1g||pwd for IV infusion after reconsti–
|1000mg/m² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine|
|Infugem||1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL||soln for IV infusion|
|paclitaxel||—||6mg/mL||soln for IV infusion after dilution||Previously untreated ovarian cancer: 175mg/m² IV over 3hrs + cisplatin; or 135mg/m² IV over 24hrs + cisplatin; repeat every 3wks
Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
|POLY (ADP-RIBOSE) POLYMERASE INHIBITOR|
|niraparib||Zejula||100mg||caps||300mg once daily until disease progression or unacceptable toxicity|
|olaparib||Lynparza||100mg, 150mg||tabs||300mg twice daily.
First-line maintenance of BRCA-mutated advanced ovarian: continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment.
Maintenance of recurrent ovarian or germline BRCA-mutated advanced ovarian: continue until disease progression or unacceptable toxicity.
|rucaparib||Rubraca||200mg, 250mg, 300mg||tabs||600mg twice daily until disease progression or unacceptable toxicity|
|topotecan||Hycamtin||4mg||pwd for IV infusion after reconsti–
tution and dilution
|1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle|
Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.
FDA-Approved Ovarian Cancer Treatments